NCI study finds that immunotherapy substantially increases survival of people with lymphomatoid granulomatosis

🔗 Access full article via NCI News Releases

According to an NCI study, patients with low-grade lymphomatoid granulomatosis who receive interferon alfa-2b, a type of immunotherapy, can live for many years after diagnosis.